217730.Kq
The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.
Business. The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and related services.
The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.14, indicating a conservative leverage position. However, the company's liquidity is assessed as medium, with a current ratio of 5.25, suggesting it has sufficient short-term assets to cover its liabilities. The price-to-book ratio of 4.41 and the price-to-tangible-book ratio of 4.41 indicate that the company's market value is significantly higher than its book value, which may reflect investor expectations of future growth or intangible assets.
Profitability metrics show a challenging financial position, with a return on equity of -0.1527 and a return on assets of -0.1286, both indicating a negative return to shareholders and asset holders. The company reported a net loss of 10,482,078,490 KRW, and an operating loss of 17,663,742,110 KRW, which is significantly below the industry median for profitability metrics. These figures suggest the company is currently unprofitable and may be investing heavily in R&D or facing operational challenges.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may increase the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at -11,675,962,560 KRW, and its free cash flow is also negative at -8,763,745,310 KRW, indicating that it is not generating sufficient cash from operations to fund its activities or growth initiatives. The capital expenditure of -660,835,490 KRW suggests the company is investing in its operations, but the negative value indicates a reduction in capital spending.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity constraints. The company's dilution risk is assessed as low, with no significant dilution potential identified in the available data. The company's valuation adjustments do not indicate any material changes to its financial position.
Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's financial statements and disclosures do not mention any recent significant events, such as mergers, acquisitions, or major regulatory actions, that would impact its financial position or strategic direction.
- The company has a conservative capital structure with a low debt-to-equity ratio of 0.14.
- The company is currently unprofitable, with a return on equity of -0.1527 and a return on assets of -0.1286.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's liquidity is assessed as medium, with a current ratio of 5.25.
- The company's growth trajectory is uncertain, with negative operating and free cash flows.
- The company's risk profile is marked by a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 217730.KQ Market data — financials · 2026-05-26